AlphAIalphai — Financial news for AI agents
manilatimes.netJUL 14 min read$MLSS

Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY

Milestone Scientific (NYSE: MLSS) reported preliminary, unaudited revenue for Q2 2026 of about $2.8M (+21% YoY) and 1H 2026 of about $5.0M (+9% YoY). The company expects medical-segment revenue up 300% YoY in Q2 and cites international order upside, plus reimbursement claims and conference plans in July.

Original reporting
manilatimes.net
Published Jul 1, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY — source image
Source · manilatimes.net
Decision brief

The 30-second read

$MLSSBullishMed
01

Why it matters

The company ties revenue growth to international orders, a surge in medical-segment growth (300% YoY in Q2), and reimbursement progress (100 claims submitted; first paid workers’ compensation claim). It also flags upcoming technology showcase at an ASPN conference (July 16-18) and plans to release full results in August.

02

Market read

Fresh preliminary revenue numbers plus specific commercialization/reimbursement milestones can drive near-term positioning ahead of the August full financial release.

03

What to watch

Medical segment is still “growing from a small base,” so percentage growth may not translate into material earnings power; dental expansion approvals may take time to monetize.

Relevance 7/10Novelty 7/10Timing: today’s preliminary Q2/1H revenue print ahead of August full results

Background

Milestone Scientific is a computerized drug-delivery instruments company; this is a preliminary, unaudited revenue update for Q2 and 1H 2026.

Company-level read

Ticker impact

$MLSSBullishMedium confidence
Context

Milestone Scientific (MLSS) reports preliminary Q2’26 revenue of ~$2.8M (+21% YoY) and 1H’26 revenue of ~$5.0M (+9% YoY).

Expected impact

Near-term upside bias versus prior expectations, with volatility risk until audited results in August.

Evidence & confidence

The release provides fresh, time-sensitive revenue datapoints and specific business drivers (international orders, medical segment growth, reimbursement claims), though it is explicitly preliminary/unaudited.

Market effects

Sector

Adds incremental signal of demand and commercialization progress in computerized injection/drug-delivery instrumentation, potentially supporting sentiment for small-cap medtech peers.

Regional

International order upside cited could modestly improve outlook for revenue mix beyond the US.

Global

Limited direct global read-through; mainly company-specific commercialization and reimbursement progress.

Counterpoint

What could challenge this read

Because figures are preliminary and unaudited, the market may discount them and focus on whether reimbursement progress converts into sustained revenue in later quarters.

Key entities

  • company
    Milestone Scientific Inc.

    NYSE-listed medical/dental injection technology developer providing preliminary Q2’26 and 1H’26 revenue estimates.

  • executive
    Eric Hines

    CEO who attributed growth to international orders and medical-segment momentum plus reimbursement progress.

  • board_member
    Dr. Dawood Sayed

    Vice Chairman and co-founder of ASPN, quoted regarding the conference theme.

Read at source← All news

Related articles

AUG 15
$CRWVMed

CoreWeave Stock Buy or Sell Debate Intensifies in 2026 After Q2 Beat and $104 Billion Backlog

CoreWeave Inc. shares closed at $105.26 on Aug. 14, 2026 after its Q2 results. Revenue rose to $2.58B from $1.21B a year earlier; adjusted operating income was $128M, but GAAP net loss widened to $626M due to higher interest expense. The company raised 2026 revenue guidance to $12.4B-$13.2B and projected adjusted operating income of $960M-$1.15B. Backlog was about $104B.

ibtimes.com.au5 min
AUG 15
$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

yahoo.com5 min
AUG 15
$CBUSMed

Cibus Q2 Earnings Call Highlights

Cibus (NASDAQ:CBUS) reported cash and cash equivalents of $20.4 million as of June 30. Management said cash burn declined 19% sequentially and 31% year over year, with existing cash expected to fund operations and capex into early Q1 2027. Guidance updates include shifting an initial Latin America rice launch to 2028 and targeting biofragrance revenue of $20 million to $40 million when commercialized.

yahoo.com6 min
AUG 15
$ICFIMed

ICF International (ICFI) Q2 2026 Earnings Call Transcript

ICF International (ICFI) reported Q2 2026 results on an earnings call, citing revenue growth from federal and a 35% rise in international government clients. Adjusted EBITDA margin was 11.2% and non-GAAP EPS rose 12%. Book-to-bill was 1.09x, pipeline $9.3B, and contracts awarded over $200M since quarter-end. Share repurchases exceeded 435k shares.

yahoo.com7 min